PURPOSE: Early mobile @entity5 can be controlled with interstitial radiotherapy (ISRT). We carried out a Phase III trial to compare the treatment results of low-dose-rate (LDR) ISRT and @entity1168 ( @entity1168 ) ISRT for early mobile @entity5 . METHODS AND MATERIALS: From April 1992 through October 1996, 59 @entity1 with @entity5 of the early mobile tongue were registered in this Phase III study. Eight @entity1 were excluded from the evaluation because of violations of the requirements for this study. Of 51 eligible @entity1 , 26 @entity1 were treated with LDR-ISRT (70 Gy/4-9 days) and 25 @entity1 with @entity1168 -ISRT (60 Gy/10 fractions/1 week). For the hyperfractionated @entity1168 -ISRT, the time interval between 2 fractions was more than 6 h. RESULTS: Five-year local control rates of the LDR and @entity1168 groups were 84% and 87% respectively. Nodal @entity3 occurred in 6 @entity1 in each group. Five-year nodal control rates of the LDR and @entity1168 groups were 77% and 76%, respectively. CONCLUSION: Hyperfractionated @entity5 has the same local control compared with continuous LDR-ISRT. Hyperfractionated @entity1168 -ISRT is an alternative treatment for continuous LDR-ISRT.

Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile XXXX .

@entity5 :: ('MESH:D009369', 'Disease') :: ['HDR-ISRT for early mobile tongue cancer', 'cancer', 'tongue cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['HDR', 'high-dose-rate'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity5 :: (MESH:D009369,Disease) :: ['tongue cancer']
